Recurrent Translocations in Topoisomerase Inhibitor-Related Leukemia Are Determined by the Features of DNA Breaks Rather Than by the Proximity of the Translocating Genes

Topoisomerase inhibitors are widely used in cancer chemotherapy. However, one of the potential long-term adverse effects of such therapy is acute leukemia. A key feature of such therapy-induced acute myeloid leukemia (t-AML) is recurrent chromosomal translocations involving AML1 (RUNX1) or MLL (KMT2...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomov, Nikolai A., Viushkov, Vladimir S., Ulianov, Sergey V., Gavrilov, Alexey A., Alexeyevsky, Daniil A., Artemov, Artem V., Razin, Sergey V., Rubtsov, Mikhail A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456246/
https://www.ncbi.nlm.nih.gov/pubmed/36077220
http://dx.doi.org/10.3390/ijms23179824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456246/
https://www.ncbi.nlm.nih.gov/pubmed/36077220
http://dx.doi.org/10.3390/ijms23179824

Ejemplares similares